Discover Thomson Reuters
First American Trust's CIO tells Reuters' Fred Katayama why he's bullish on Biogen's prospects. The biotech firm's stock surged after its Alzheimer's drug showed positive results in a mid-stage trial.
05:59
07:57
02:10
01:45
07:21
01:58
01:29
02:07
01:53
02:09
01:49
01:05
00:37
01:10
01:46
01:13
01:37
01:36
01:42